BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 91 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q4 2014. The put-call ratio across all filers is 0.93 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2017 | $230,000 | -10.5% | 43,926 | -4.8% | 0.00% | 0.0% |
| Q2 2017 | $257,000 | -30.7% | 46,149 | +4.5% | 0.00% | 0.0% |
| Q1 2017 | $371,000 | +27.5% | 44,174 | -3.8% | 0.00% | 0.0% |
| Q4 2016 | $291,000 | +36.0% | 45,913 | -5.6% | 0.00% | 0.0% |
| Q3 2016 | $214,000 | +55.1% | 48,613 | 0.0% | 0.00% | 0.0% |
| Q2 2016 | $138,000 | -42.0% | 48,613 | -42.4% | 0.00% | 0.0% |
| Q1 2016 | $238,000 | -82.3% | 84,469 | -35.1% | 0.00% | -83.3% |
| Q4 2015 | $1,343,000 | -9.6% | 130,148 | -0.1% | 0.01% | -14.3% |
| Q3 2015 | $1,485,000 | +26.0% | 130,253 | +65.0% | 0.01% | +40.0% |
| Q2 2015 | $1,179,000 | +45.9% | 78,936 | -11.8% | 0.01% | +66.7% |
| Q1 2015 | $808,000 | +1.1% | 89,460 | +36.2% | 0.00% | 0.0% |
| Q4 2014 | $799,000 | +51.9% | 65,677 | +22.1% | 0.00% | +50.0% |
| Q3 2014 | $526,000 | -23.7% | 53,799 | -0.4% | 0.00% | -33.3% |
| Q2 2014 | $689,000 | +1926.5% | 54,005 | +144.5% | 0.00% | – |
| Q2 2013 | $34,000 | – | 22,090 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| VHCP Management, LLC | 1,744,356 | $18,455,000 | 9.59% |
| RA Capital Management | 4,347,456 | $45,996,000 | 3.30% |
| Cormorant Asset Management, LP | 1,168,000 | $12,357,000 | 2.84% |
| Baker Brothers Advisors | 5,867,031 | $62,073,000 | 0.79% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 907,920 | $9,606,000 | 0.39% |
| QVT Financial LP | 525,734 | $5,562,000 | 0.32% |
| EAM Investors, LLC | 114,548 | $1,212,000 | 0.22% |
| FRANKLIN STREET ADVISORS INC /NC | 93,000 | $984,000 | 0.20% |
| THB ASSET MANAGEMENT | 301,529 | $3,190,000 | 0.19% |
| TPG Group Holdings (SBS) Advisors, Inc. | 1,162,269 | $12,297,000 | 0.13% |